Each of these AKT inhibitors dose dependently inhibited AKT kinase activity in the non-small-cell lung carcinoma (NSCLC) cell line EBC1 as determined by phosphorylation of three AKT substrates (PRAS40, GSK3β, and BAD) in whole-cell lysates (Figure 1A and Figure 1—figure supplement 1). The gene discussed is BAD; the disease is non-small cell lung carcinoma.